BioCentury | Oct 11, 2019
Company News

Management tracks: Chan leaving FDA’s China office; plus Galera, Aridis and Palladio

...and an executive director of Realm Therapeutics plc, which was acquired by Essa Pharma Inc. (NASDAQ:EPIX...
BioCentury | Aug 10, 2019
Company News

Management tracks: Melinta, Editas, Accelerate, Santhera

...He was previously CEO of Realm Therapeutics plc, which was acquired by ESSA Pharma Inc. (NASDAQ:EPIX...
BioCentury | Jul 5, 2017
Company News

Management tracks

...Boston, Mass.) named Simon Jones president and CEO. He was VP of biology at EPIX Pharmaceuticals Inc. (Pink:EPIX...
BioCentury | Dec 1, 2016
Financial News

Essa Pharma completes debt financing

...received seven-year warrants to purchase up to 149,532 shares at $2.14. Essa Pharma Inc. (TSX:EPI; NASDAQ:EPIX...
BioCentury | Jan 18, 2016
Financial News

Essa Pharma completes private placement of units

...Essa Pharma Inc. (TSX:EPI; NASDAQ:EPIX), Vancouver, B.C. Business: Cancer Date completed: 2016-01-14 Type: Private placement of...
BioCentury | Jan 11, 2016
Financial News

Essa Pharma proposes private placement of units

...Essa Pharma Inc. (TSX:EPI; NASDAQ:EPIX), Vancouver, B.C. Business: Cancer Date announced: 2016-01-06 Type: Private placement of...
BioCentury | Dec 7, 2015
Clinical News

EPI-506: Phase I/II started

...Essa Pharma Inc. (TSX:EPI; NASDAQ:EPIX), Vancouver, B.C. Product: EPI-506 Business: Cancer Molecular target: Androgen receptor Description...
BioCentury | Mar 11, 2013
Company News

Vivus endocrine/metabolic news

...have one or more weight-related condition. FMC's nominees include Michael Astrue, formerly interim CEO at Epix Pharmaceuticals Inc....
BioCentury | Mar 9, 2013
Company News

FMC wants new Vivus board, strategy

...drug in the U.S. in September. FMC's nominees include Michael Astrue, formerly interim CEO at Epix Pharmaceuticals Inc....
BioCentury | Oct 17, 2011
Company News

Amgen, Epix autoimmune news

...to develop and commercialize oral S1PR1 agonists with Predix Pharmaceuticals Inc. , which merged with Epix...
...BioCentury, Aug. 7, 2006 & Aug. 21, 2006). Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Epix Pharmaceuticals Inc. (Pink:EPIX...
Items per page:
1 - 10 of 336
BioCentury | Oct 11, 2019
Company News

Management tracks: Chan leaving FDA’s China office; plus Galera, Aridis and Palladio

...and an executive director of Realm Therapeutics plc, which was acquired by Essa Pharma Inc. (NASDAQ:EPIX...
BioCentury | Aug 10, 2019
Company News

Management tracks: Melinta, Editas, Accelerate, Santhera

...He was previously CEO of Realm Therapeutics plc, which was acquired by ESSA Pharma Inc. (NASDAQ:EPIX...
BioCentury | Jul 5, 2017
Company News

Management tracks

...Boston, Mass.) named Simon Jones president and CEO. He was VP of biology at EPIX Pharmaceuticals Inc. (Pink:EPIX...
BioCentury | Dec 1, 2016
Financial News

Essa Pharma completes debt financing

...received seven-year warrants to purchase up to 149,532 shares at $2.14. Essa Pharma Inc. (TSX:EPI; NASDAQ:EPIX...
BioCentury | Jan 18, 2016
Financial News

Essa Pharma completes private placement of units

...Essa Pharma Inc. (TSX:EPI; NASDAQ:EPIX), Vancouver, B.C. Business: Cancer Date completed: 2016-01-14 Type: Private placement of...
BioCentury | Jan 11, 2016
Financial News

Essa Pharma proposes private placement of units

...Essa Pharma Inc. (TSX:EPI; NASDAQ:EPIX), Vancouver, B.C. Business: Cancer Date announced: 2016-01-06 Type: Private placement of...
BioCentury | Dec 7, 2015
Clinical News

EPI-506: Phase I/II started

...Essa Pharma Inc. (TSX:EPI; NASDAQ:EPIX), Vancouver, B.C. Product: EPI-506 Business: Cancer Molecular target: Androgen receptor Description...
BioCentury | Mar 11, 2013
Company News

Vivus endocrine/metabolic news

...have one or more weight-related condition. FMC's nominees include Michael Astrue, formerly interim CEO at Epix Pharmaceuticals Inc....
BioCentury | Mar 9, 2013
Company News

FMC wants new Vivus board, strategy

...drug in the U.S. in September. FMC's nominees include Michael Astrue, formerly interim CEO at Epix Pharmaceuticals Inc....
BioCentury | Oct 17, 2011
Company News

Amgen, Epix autoimmune news

...to develop and commercialize oral S1PR1 agonists with Predix Pharmaceuticals Inc. , which merged with Epix...
...BioCentury, Aug. 7, 2006 & Aug. 21, 2006). Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Epix Pharmaceuticals Inc. (Pink:EPIX...
Items per page:
1 - 10 of 336